Simonsen G S, Andersen B M, Digranes A, Harthug S, Jacobsen T, Lingaas E, Natås O B, Olsvik O, Ringertz S H, Skulberg A, Syversen G, Sundsfjord A
Department of Microbiology, University Hospital of Tromso, Norway.
Scand J Infect Dis. 1998;30(5):465-8. doi: 10.1080/00365549850161449.
The faecal carrier rate of vancomycin resistant enterococci (VRE) was surveyed among 616 patients in selected departments of 7 Norwegian hospitals. One Enterococcus gallinarum isolate harbouring a vanB2 element was recovered from a child with malignant disease treated with vancomycin and ceftazidime. No vancomycin resistant Enterococcus faecalis or Enterococcus faecium were detected and no VRE isolates of the VanA type were identified. The low level of VRE carriage corresponds to the limited use of glycopeptide antibiotics for human therapeutic purposes in Norway. It indicates a low risk of acquiring VRE infections in Norwegian hospitals.
在挪威7家医院的特定科室中，对616名患者的耐万古霉素肠球菌（VRE）粪便携带率进行了调查。从一名接受万古霉素和头孢他啶治疗的恶性疾病患儿中分离出一株携带vanB2元件的鹑鸡肠球菌。未检测到耐万古霉素的粪肠球菌或屎肠球菌，也未鉴定出VanA类型的VRE分离株。VRE携带率较低与挪威将糖肽类抗生素用于人类治疗目的的使用受限相对应。这表明挪威医院获得VRE感染的风险较低。
